Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Hyderabad-based pharma major Aurobindo Pharma on Tuesday announced that its subsidiary CuraTeQ Biologics had received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market cancer drug Dazublys in the country.

 

The drug, a biosimilar version of the molecule trastuzumab, is used to treat human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. It regulates the HER2 protein that promotes tumour growth. The development follows Dazublys’ approval by the European Commission (EC) for the European Union (EU) market in July this year.

 

The company said Dazublys is the fourth CuraTeQ biosimilar to receive MHRA approval,